Long-term cost and efficacy analysis of latanoprost versus timolol in glaucoma patients in Germany

International Journal of Ophthalmology

Volumn 6, Issue 2, 2013, Pages 155-159

  Thelen, Ulrich ^a   Schnober, Dietmar ^b   Schölzel, Sonja ^c   Kristoffersen, Michael S ^d   Nelson, Lindsay A ^d   Stewart, Jeanette A ^d   Stewart, William C ^d  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b University of Freiburg ^*

^c UNIVERSITY OF FREIBURG   (Germany)

^d PRN Pharmaceutical Research Network LLC   (United States)

Author keywords

Economic; Efficacy; Germany; Glaucoma; Latanoprost; Safety; Timolol

Indexed keywords

EID: 84888088192     PISSN: 22223959     EISSN: 22274898     Source Type: Journal    
DOI: 10.3980/j.issn.2222-3959.2013.02.09     Document Type: Article

References (19)

1. Camras CB, Alm A, Watson P., Stjernschantz J. Latanoprost, a prostaglandin analog, for glaucoma therapy. Efficacy and safety after 1 year of treatment in 198 patients. Ophthalmology. 2006; 103(11): 1916-1924.
2. Stewart WC, Konstas AG, Nelson L.A., Kruft B. Meta-analysis of 24-hour intraocular pressure studies evaluating the efficacy of glaucoma medicines. Ophthalmology. 2008; 115(7): 1117-1122.
3. Van der Valk R, Webers C, Schouten J, Zeegers MP, Hendrikse F, Prins MH. Intraocular pressure-lowering effects of all commonly used glaucoma drugs - a meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112(7): 1177-1185.
4. Van der Valk R, Webers C, Lumley T, Hendrikse F, Prins MH, Schouten JS. A network meta-analysis combined direct and indirect comparisons between glaucoma drugs to rank effectiveness in lowering intraocular pressure. J Clin Epidemiol. 2009; 62(12): 1279-1283.
5. Day DG, Schacknow PN, Sharpe E.D., Ellyn JC, Kulze JC, 3rd, Threlkeld AB, Jones ED, Brown RH, Jenkins JN, Stewart WC. A persistency and economic analysis of latanoprost, bimatoprost, or beta-blockers in patients with open-angle glaucoma or ocular hypertension. J Ocul Pharmacol Ther. 2004; 20(5): 383-392.
6. Schwartz GF, Reardon G, Mozaffari E. Persistency with latanoprost or timolol in primary open-angle glaucoma suspects. Am J Ophthalmol. 2004; 137(1 Suppl): 13-16.
7. Stewart WC, Stewart JA, Mychaskiw MA. Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia and the United Kingdom, using a decision-analytic health economic model. Eye. 2009; 23(1): 132-140.
8. Book SA. New York: McGraw-Hill, Inc; 1978. Essentials of Statistics.
9. Watson PG. Latanoprost. Two years' experience of its use in the United Kingdom. Ophthalmology. 1998; 105(1): 82-87.
10. Konstas AG, Maltezos AC, Gandi S, Hudgins A.C., Stewart WC. Comparison of 24-hour intraocular pressure reduction with two dosing regimens of latanoprost and timolol maleate in patients with primary open-angle glaucoma. Am J Ophthalmol. 1999; 128(1): 15-20.
11. Alm A, Stjernschantz J. Effect on intraocular pressure and side effects of 0.005% latanoprost applied once daily, evening or morning. Ophthalmology. 1995; 102(12): 1745-1752.
12. Stewart WC. Clinical Practice of Glaucoma. Thorofare: SLACK, Inc; 1990.
13. Ritch R. The Glaucomas. St. Louis: Mosby-Year Book, Inc; 1996.
14. Hedman K, Watson PG, Alm A. The effect of latanoprost on intraocular pressure during 2 years of treatment. Surv Ophthalmol. 2002; 47: S65-76. Suppl. 1.
15. Holló G, Thelen U, Teus MA, Quaranta L, Ferkova S, Babić N, Misiuk-Hojlo M, Mikropoulos DG, Kaluzny BJ, Kozobolis V, Januleviciene I, Kóthy P, Camara C, Russo A, Krzyzanowska-Berkowska P, Cieślińska I, Stewart JA, Kristoffersen MS, Nelson LA, Stewart WC. Long-term outcomes of prostaglandin analog versus timolol maleate in ocular hypertensive or primary open-angle glaucoma patients in Europe. J Ocul Pharmacol Ther. 2011; 27(5): 493-498.
16. Van Gestel A., Webers CA, Severens J.L., Beckers HJ, Jansonius NM, Hendrikse F, Schouten JS. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma. Acta Ophthalmol. 2012; 90(1): 20-31.
17. Stewart WC, Stewart JA, Nelson L.A., Kruft B. Physician attitudes regarding prostaglandin treatment for glaucoma in the United States and Europe. Eur J Ophthalmol. 2008; 18(2): 199-204.
18. Stewart WC, Castelli WP. Systemic side effects of topical β-adrenergic blockers. Clin Cardiol. 1996; 19: 691-697.
19. Stewart WC, Garrison PM. Beta-blocker-induced complications and the glaucoma patient: newer treatments to help reduce systemic side effects. Arch Intern Med. 1998; 158(3): 221-226.